Evidence map›Paper›PMID 37896898›Full record

ArticleViruses2023

Characteristics of Anti-Measles Immunity in Lung Transplant Candidates.

Valentina B Polishchuk, Mikhail P Kostinov, Aleksey A Ryzhov, Natalia A Karchevskaya, Irina L Solov'eva, Alexander P Cherdantsev, Aristitsa M Kostinova, Arseniy A Poddubikov

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Viruses, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Valentina B PolishchukLaboratory for Vaccination and Immunotherapy of Allergic Diseases, I.I. Mechnikov Research Institute of Vaccines and Sera, 105064 Moscow, Russia.
Mikhail P KostinovLaboratory for Vaccination and Immunotherapy of Allergic Diseases, I.I. Mechnikov Research Institute of Vaccines and Sera, 105064 Moscow, Russia.
Aleksey A RyzhovLaboratory for Vaccination and Immunotherapy of Allergic Diseases, I.I. Mechnikov Research Institute of Vaccines and Sera, 105064 Moscow, Russia.
Natalia A KarchevskayaDepartment of Thoracic and Abdominal Surgery, N.V. Sklifosovsky Research Institute for Emergency Medicine, 127994 Moscow, Russia.
Irina L Solov'evaDepartment of Pediatrics, Ulyanovsk State University, 432017 Ulyanovsk, Russia.
Alexander P CherdantsevDepartment of Pediatrics, Ulyanovsk State University, 432017 Ulyanovsk, Russia.
Aristitsa M KostinovaDepartment of Epidemiology and Modern Vaccination Technologies, I.M. Sechenov First Moscow State Medical University (Sechenovskiy University), 119991 Moscow, Russia.ORCID 0000-0002-0584-2376
Arseniy A PoddubikovN.V. Sklifosovskiy Institute of Clinical Medicine, I.M. Sechenov First Moscow State Medical University (Sechenovskiy University), 119991 Moscow, Russia.
Sechenov University · RUResearch Institute of Vaccines and Sera. Mechnikov of the Russian Academy of Medical Sciences · RUUlyanovsk State University · RUResearch Institute of Emergency Care · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Measles has not yet been eradicated; therefore, its outbreaks are still reported throughout the world. Like any infection, measles is dangerous for immunocompromised patients. Levels of anti-measles IgG antibodies were measured in 157 patients aged 17 to 72, who were placed on the lung transplant waiting list. Measurements were undertaken by enzyme-linked immunosorbent assay (ELISA) using the VectoMeasles-IgG kit (Russia). The proportion of patients seronegative for measles was 19% (30/157). Correlation was detected between patients' age and their levels of anti-measles antibodies, with higher proportions of patients having undetectable titers (25.5-28.9%) or low antibody levels (38.3-44.4%) in the young age groups (17-29 and 30-39 years old). There were no differences between male and female patients in levels of anti-measles antibodies or in the proportion of seronegative individuals. Analyses of antibody levels with regard to type of disease revealed the highest rate of seronegative results in cystic fibrosis patients (34.4%, 11/32). Overall, 19% of lung transplant candidates, mostly young people and cystic fibrosis patients, did not have protective immunity against measles.

Indexed as

Cystic FibrosisLung TransplantationMeaslesAdolescentAntibodies, ViralEnzyme-Linked Immunosorbent AssayFemaleHumansImmunoglobulin GMaleMeasles virusAntibodies, ViralImmunoglobulin Ganti-measles immunitylung transplantmeasles

Identifiers

PMID37896898
PMCPMC10612083
OpenAlexW4387772724

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.